Skip to main content
. 2014 Jan;85(1):91–104. doi: 10.1124/mol.113.089482

Fig. 9.

Fig. 9.

The polymorphic variant Val76Met reduces potency of a series of ligands at human GPR35a. The potencies of lodoxamide (A), bufrolin (B), zaprinast (C), and cromolyn disodium (D) were compared between human Val76 GPR35a and Met76 GPR35a using the BRET-based β-arrestin-2 interaction assay. In each case, data are presented as a percentage of the maximal effect of zaprinast at the appropriate variant.